• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$0.24 -$0.01 (-4.00%)

Quote as of

NORTHWEST BIOTHRPUTCS INC

NASDAQOTCBB:NWBO.OB

Northwest Bio Provides Update On DCVax®-L Brain Cancer Trial

Northwest Bio Awarded $5.5 Million German Government Grant

Why You Should Be Interested In Northwest Biotherapeutics And ImmunoCellular Therapeutics

Northwest Bio and Fraunhofer IZI Announce Milestones Reached

Dendreon Will Plummet On DCVax Approval

Northwest Bio Welcomes New Additions to the Board of Directors

Northwest Bio Partners With King's College Hospital and King's College London for Programs in Europe

Northwest Biotherapeutics, Red Cross team up on cancer vaccine

NW Bio Reaches 30 Clinical Trial Sites Ahead of End-of-Q1 Projection

Northwest Biotherapeutics requests withdrawal of registration statement

NW Bio to Present Today at the OneMedForum SF 2012 Conference

NW Bio Reaches 25 Clinical Trial Sites Open and Recruiting By the End of Q4, 2011

Northwest Biotherapeutics (NWBO): Initiating with an Outperform Rating - Analyst Blog

Northwest Biotherapeutics (NWBO): Initiating with an Outperform Rating

Northwest Bio Implements Major Balance Sheet Clean-Up

Northwest Bio Announces Transactions for $5.4 Million in New Financing

Northwest Bio to Present at Society of Neuro-Oncology Annual Meeting

Northwest Bio Announces Interview of CEO Linda Powers in Today's CEO/CFO Publication

Standard & Poor's Initiates Factual Stock Report Coverage on Northwest Biotherapeutics, Inc.

NORTHWEST BIO Announces Initiation of S&P Coverage, With Publication of First Company Stock Report

NORTHWEST BIO Announces Positive Third Quarter Progress

NWBT Highlights Cost Effectiveness of DCVax® in View of Recent Immunotherapy Pricing Concerns

NWBT Announces Further Expansion of Clincal Sites in Ongoing Brain Cancer Trial

Key investments should continue to propel Northwest Biotherapeutics (NAB,NAS:NWBO,DNDN)

"Growing Momentum and Recognition" for Northwest Biotherapeutics Should Continue

Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe

Northwest Biotherapeutics announces $4.55M equity investment

Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe

Northwest Biotherapeutics names new CEO, COO

Northwest Biotherapeutics Announces Change and Expansion of Management Team

Northwest Biotherapeutics Announces Change and Expansion of Management Team

Northwest Biotherapeutics lands funding

Northwest Biotherapeutics Announces Series of Financing Arrangements

Northwest Biotherapeutics Announces Series of Financing Arrangements

Northwest Biotherapeutics Announces Series of Financing Arrangements

Investing in Cancer Therapy? Consider Companies Engaged in Immunotherapy

Northwest Biotherapeutics Further Expands Ongoing Brain Cancer Trial

Northwest Biotherapeutics adds new clinical sites for brain cancer trial

Northwest Biotherapeutics Further Expands Ongoing Brain Cancer Trial

Northwest Biotherapeutics Further Expands Ongoing Brain Cancer Trial

See More Articles...